Tebentafusp

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C94208

HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

1874157-95-5

C94208

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978

CTRP

GDC

FDA

A fusion protein containing a modified form of human T-cell receptor (TCR) specific for the gp100 antigen and fused to an anti-CD3 single-chain antibody fragment, with potential antineoplastic activity. Upon direct intratumoral administration of tebentafusp into the melanoma lesion, the TCR moiety of this agent targets and binds to the tumor associated antigen (TAA) gp100 presented on the melanoma tumor cell; the anti-CD3 fragment moiety binds to CD3- expressing T lymphocytes, thereby selectively cross-linking tumor cells and T-lymphocytes. This may lead to the recruitment of cytotoxic T lymphocytes (CTL) to the T lymphocyte/tumor cell aggregates and result in CTL-mediated death of gp100-expressing melanoma cancer cells.

Tebentafusp

N658GY6L3E

Tebentafusp

TEBENTAFUSP

ImmTAC-gp100

Monoclonal T-cell Receptor Anti-CD3 scFv Fusion Protein IMCgp100

Kimmtrak

Tebentafusp-tebn

KIMMTRAK

IMCgp100

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C41037

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1909

Tebentafusp

Tebentafusp

Monoclonal T-cell Receptor Anti-CD3 scFv Fusion Protein IMCgp100

686537

CL426021

686537

686537

Tebentafusp

Thesaurus:C94208

Tebentafusp

Pharmacologic Substance

Immunologic Factor

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1512